Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors

OBJECTIVE: rhuMAb 2C4 (pertuzumab, RO4368451), a human epidermal growth factor receptor-2 (HER2) targeted antibody that binds to an epitope distinct from trastuzumab, blocks ligand-associated heterodimerization of HER2 with other HER receptor family members. This study evaluated the toxicity, pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Noboru, Yamada, Yasuhide, Fujiwara, Yutaka, Yamada, Kazuhiko, Fujisaka, Yasuhito, Shimizu, Toshio, Tamura, Tomohide
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661001/
https://www.ncbi.nlm.nih.gov/pubmed/19261664
http://dx.doi.org/10.1093/jjco/hyp006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661001/
https://www.ncbi.nlm.nih.gov/pubmed/19261664
http://dx.doi.org/10.1093/jjco/hyp006

Ejemplares similares